US FDA, CMS and NIH are hoping to create a “single front door” for research. Article outlining collaboration on real-world evidence suggests one path forward.
The heads of FDA and CMS are outlining a vision for collaboration on development of real-world evidence ahead of the transition to a new presidential administration.
FDA Commissioner Robert Califf, Deputy Commissioner for Medical Products Rachel Sherman, and Acting CMS Administrator Andy Slavitt published a “
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
